Rebound-associated vertebral fractures after denosumab discontinuation in a lung cancer patient with bone metastases

Denosumab is a commonly used antiresorptive treatment in patients with osteoporosis or solid tumours with bone metastases. Upon denosumab discontinuation, a rebound phenomenon can occur that results in an increased (vertebral) fracture risk. This phenomenon is well-known in the setting of osteoporos...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Jolan Dupont, Wesley Appermans, Marian Dejaeger, Isabelle Wauters, Michaël R. Laurent, Evelien Gielen
Format: Artigo
Langue:Inglês
Publié: Elsevier 2022-06-01
Collection:Bone Reports
Sujets:
Bone turnover markers
Denosumab
Osteoporosis
Vertebral fractures
Rebound phenomenon
Accès en ligne:http://www.sciencedirect.com/science/article/pii/S2352187222004168
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires